A multicentric, single blind, parallel, randomized, phase-IV non-inferiority study to evaluate the immunogenicity and safety of BE's combined liquid pentavalent DTwP-rHepB-HIB vaccine administered to 6-8 week old healthy Indian infants at 6-10-14 weeks schedule in comparison with a marketed SIIL's Pentavac SD vaccine

Trial Profile

A multicentric, single blind, parallel, randomized, phase-IV non-inferiority study to evaluate the immunogenicity and safety of BE's combined liquid pentavalent DTwP-rHepB-HIB vaccine administered to 6-8 week old healthy Indian infants at 6-10-14 weeks schedule in comparison with a marketed SIIL's Pentavac SD vaccine

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Biological E Limited
  • Most Recent Events

    • 04 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top